When to Start Population-Wide Screening for Chronic Kidney Disease
This study found that, based on conventional benchmarks for cost-effectiveness in medicine, initiating population-wide CKD screening with SGLT2 inhibitors at age 55 years would be cost-effective.
Authors
- Jeremy D. Goldhaber‐Fiebert (ORCID: https://orcid.org/0000-0002-4007-5192)
- Glenn M. Chertow (ORCID: https://orcid.org/0000-0002-7599-0534)
- Joshua A. Salomon (ORCID: https://orcid.org/0000-0003-3929-5515)
- Marika Cusick (ORCID: https://orcid.org/0000-0002-1750-5246)
- Rebecca L. Tisdale (ORCID: https://orcid.org/0000-0003-2749-6889)
- Douglas K Owens
Institutions
- VA Palo Alto Health Care System (US)
- Stanford Medicine (US)
- Stanford University (US)
Publication Details
- Journal
- JAMA Health Forum
- Published
- 2024-11-08
- DOI
- https://doi.org/10.1001/jamahealthforum.2024.3892
- Citations
- 6
- Primary Topic
- Chronic Kidney Disease and Diabetes
- Type
- article
- Field-Weighted Citation Impact
- 2.04